Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States and announce company management's participation in two upcoming investor conferences. Medexus has seen an encouraging market response to GRAFAPEX™ in the weeks... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of Medexus's rights to Gleolan® in the United States, to terminate the license, supply, and distribution agreement between the parties and return responsibility for Gleolan® in the United States to NXDC as of a date no later than... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX™ (treosulfan) for Injection is now commercially available in the United States. "We are pleased to report this positive development, which marks a strategically important step forward for our business and, importantly, will now benefit eligible patients across... Read More

Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health (Ontario Public Drug Programs) and Ontario Health (Cancer Care Ontario) for Trecondyv® (treosulfan for injection). The Ontario Public Drug Programs will now reimburse eligible claims made for Trecondyv®, subject to satisfaction... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus's results for its third fiscal quarter ended December 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on February 5, 2025. To participate in the call,... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the "Offering") of 7,500,000 common shares of the Company (the "Common Shares") at a public offering price of $4.00 per Common Share for aggregate gross proceeds to the... Read More

The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ TORONTO and CHICAGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX: MDP), is pleased to announce the pricing and terms of its previously announced overnight marketed underwritten offering (the “Offering”) of 7,500,000 common shares of the Company... Read More

TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”). The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the... Read More

Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launch Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 22, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update regarding the successful completion of the regulatory review process for GRAFAPEX™ (treosulfan)... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincial Health Services Authority (PHSA), a publicly funded health service provider in the Canadian province, for a new approved indication for Trecondyv® (treosulfan for injection) to be listed on the BC Cancer Benefit Drug List and... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - December 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a fourth amendment to its February 2021 exclusive license agreement with medac relating to commercialization of treosulfan in the United States. Among other things, the fourth amendment adjusts the unpaid regulatory milestone payments... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership... Read More

Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 million Management to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, November 8, 2024 to discuss Medexus's results for its second fiscal quarter ended September 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on November 7, 2024. To participate in the call,... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review period for the New Drug Application for treosulfan by three months. The FDA has set a new PDUFA target action date of January 30, 2025. The FDA... Read More

Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 million Management to host conference call at 8:00 AM Eastern time on Thursday, August 8, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on August 7, 2024. To participate in the call, please dial the... Read More

FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2024 (the... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2024. To participate in the... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug Application for treosulfan. Medexus expects that the FDA will complete its... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoject®, have elected not to appeal the trial court decision. Medexus and medac initiated the litigation in... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event : 2024 Bloom Burton & Co. Healthcare Investor Conference Date : April 16-17, 2024 Location : Toronto, Ontario Medexus Presentation :... Read More

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application... Read More

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on February 7, 2024. To participate in the call,... Read More

Topical terbinafine has been widely used in other markets to treat fungal nail infections If and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million on an annual basis* Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that Health Canada recently accepted for review Medexus's new... Read More

Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performance Management to host conference call at 8:00 AM Eastern time on Thursday, November 9, 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 8, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, 2023 to discuss Medexus's results for its second fiscal quarter ended September 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on November 8, 2023. To participate in the call,... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed bought-deal public offering ( Offering ) of units ( Units ), Medexus has issued an additional 508,484 Units at a price of C$2.95 per Unit for an additional C$1.5 million in gross proceeds following exercise in full by Research... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately US$37.5 million) to Computershare Trust Company of Canada as trustee for holders of Medexus's 6% unsecured convertible debentures due October 16, 2023 (TSX: MDP.DB). Under the terms of the indenture governing the... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900 units ( Units ) at a price of C$2.95 per Unit for aggregate gross proceeds to Medexus of C$10,000,205 ( Offering ). The net proceeds from the Offering, after deducting underwriting discounts and commissions and... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment to its February 2021 exclusive license agreement with medac GmbH relating to commercialization of treosulfan in the United States. Among other things, the third amendment extends the agreed outside date for FDA... Read More

All director nominees reelected and all other company proposals approved by shareholders Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 9, 2023 as directors through the next annual... Read More

TORONTO and CHICAGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (" Medexus " or the " Company ") (TSX: MDP) (OTCQX: MEDXF) , is pleased to announce that it has entered into an agreement with Research Capital Corporation, as sole bookrunner and sole underwriter (the “ Underwriter ”), pursuant to which the Underwriter has agreed to purchase, on a bought-deal basis, 3,389,900 units of the Company (the “... Read More

Medexus expects net proceeds, together with projected cash on hand, to fully satisfy convertible debentures in cash at maturity in October 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 5, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company's senior secured credit agreement with BMO as agent and lender. The amendment provides for a US$18 million... Read More

Poster presentation at National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 highlights effective prophylaxis, control of bleeding episodes, and consistent safety profile Phase 3/4 data presentation follows FDA acceptance for review of IXINITY® supplemental Biological License Application for pediatric patients Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 17, 2023) - Medexus... Read More

Fiscal Q1 2024 revenue reflects a 37% increase over fiscal Q1 2023, demonstrating strong revenue growth and continued overall performance Management to host conference call at 8:00 AM Eastern time on Thursday, August 10, 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time. Event : SHARE Series Date : August 14, 2023 Location : Virtual Presentation Medexus Presentation : Monday, August 14 at 8:30 AM Eastern time Ken d'Entremont,... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 10, 2023 to discuss Medexus's results for its first fiscal quarter ended June 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on August 9, 2023. To participate in the call, please dial... Read More

Preliminary estimates indicate revenue is expected to exceed US$31 million for fiscal quarter ended June 30, 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 12, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company's fiscal quarter ended June 30, 2023 (the company's fiscal Q1 2024). All dollar amounts in this news release are in US... Read More

Management to Host Conference Call at 8:00 Am Eastern Time on Thursday, June 22, 2023 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2023 (the company's fiscal Q4 2023 and fiscal year 2023). All... Read More

Expanded indication would cover patients 12 years of age or younger, a population that comprises approximately one in three patients treated for hemophilia B in the United States Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 15, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration ( FDA ) recently accepted for review Medexus's supplemental... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 14, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 22, 2023 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on June 21, 2023. To participate in the call,... Read More

Princess Margaret Cancer Center's retrospective analysis found a 30% improvement (83.2% vs 53.2%) in one-year overall survival for patients treated with treosulfan, among other positive findings Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 13, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret... Read More

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the LD Micro Invitational XIII from June 6-8 2023. Event : LD Micro Invitational XIII Date : June 6-8, 2023 Location : Luxe Sunset Boulevard Hotel, California Medexus Presentation : Tuesday, June 6 at 2:30 PM Pacific time Ken... Read More

NCIB will commence on May 15, 2023 and is expected to continue through the debentures' October 2023 maturity date NCIB purchases will deleverage Medexus's balance sheet and lead to lower overall debt levels and reduced future debt service obligations in preparation for the debentures' October 2023 maturity date Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 10, 2023) - Medexus Pharmaceuticals (TSX: MDP) (TSX:... Read More

ISPOR 2023 Presentation Shows 33% Lowered Costs with Gleolan Compared to Conventional White Light Surgery Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today presented data demonstrating a 33% cost savings with Gleolan® (aminolevulinic acid HCl) oral solution, compared to conventional white light surgery, in US patients with high-grade glioma. The... Read More

TORONTO and CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference from April 25 to 26, 2023. Event : 2023 Bloom Burton & Co. Healthcare Investor Conference Date : April 25-26, 2023 Location : Toronto, Ontario Medexus Presentation : Tuesday, April 25 at 9:30... Read More

TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter and full fiscal year ended March 31, 2023, and, in addition, is providing an additional business update to shareholders and other stakeholders. All dollar amounts in this news release are in US dollars unless specified otherwise.... Read More

TORONTO and CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that the company has secured Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group company focused on medical dermatological treatments for skin health. The product, which Medexus will submit for Health Canada approval later this year, has... Read More

TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO. The credit agreement provides for a US$35 million term loan facility and a US$3.5 million revolving loan facility for working capital. The term loan facility benefits from an additional US$20 million uncommitted accordion feature, which... Read More

TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023. Event : 35th Annual Roth Conference Date : March 12-14, 2023 Location : Dana Point, California Medexus Presentation : March 14 at 1:00 PM Pacific time (4:00 PM Eastern time) Ken d’Entremont,... Read More

Results reflect growth across all leading prescription products, demonstrating continued track record of strong overall performance Management to host conference call at 8:00 AM Eastern Time on Thursday, February 9, 2023 TORONTO and CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the... Read More

Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors Appointments bolster Medexus board’s medical and financial expertise, particularly in the United States TORONTO and CHICAGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA,... Read More

TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrrolate oral solution 1mg/5mL). Cuvposa will be listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Régime de... Read More

TORONTO and CHICAGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quarter ended December 31, 2022. Medexus expects to file its financial statements and MD&A after markets close on February 8, 2023. To participate in the call, please dial the... Read More

TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023) and provide additional business updates to shareholders and other stakeholders. All dollar amounts in this press release are in US dollars unless specified... Read More

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended September 30, 2022 (the company’s fiscal Q2 2023). All dollar amounts in this press release are in U.S. dollars unless specified otherwise. Medexus expects to deliver total revenue between $27.0 million and $27.5 million in fiscal Q2 2023. This will represent... Read More

Medexus’s borrowing capacity under its revolving credit facility increases by US$5.0 million, from US$20.0 million to US$25.0 million Transaction strengthens Medexus’s balance sheet, providing additional operating liquidity Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company’s revolving credit facility with a syndicate of lenders agented by MidCap Funding IV Trust (... Read More

FDA requests further information from medac, continues to engage with treosulfan NDA Medexus continues to focus on maintaining momentum and growth in its North American on-market portfolio, and is now recognizing 100% of Gleolan U.S. net sales as of September Medexus to host live webcast on September 21, 2022 at 11:00 AM Eastern Time On Friday, September 16, Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) was... Read More

All director nominees reelected for the coming year All other proposals also approved by shareholders Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus’s management information circular dated August 5, 2022 as directors through the next annual meeting. Shareholders also voted in favor of the... Read More

Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023 Management to host conference call at 8:00 AM Eastern Time on Tuesday, August 9, 2022 Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the... Read More

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022 to discuss Medexus’s results for its first quarter ended June 30, 2022. Medexus expects to file its financial statements and MD&A after markets close on August 8, 2022. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S.... Read More

FDA decision expected within six months of acceptance Pivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for treosulfan ( NDA ) with the U.S. Food and Drug Administration ( FDA ). The current submission... Read More

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March 31, 2022. All dollar amounts in this press release are in United States dollars unless specified otherwise. Financial Highlights Delivered total revenue of $20.3 million in fiscal Q4 2022, an increase of 15%... Read More

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022 to discuss Medexus’s results for its fourth quarter and fiscal year ended March 31, 2022. Medexus expects to file its financial statements and MD&A after markets close on June 22, 2022. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for... Read More

Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm Study results accepted for publication with American Journal of Hematology, now available online Medexus to host webconference with key opinion leader to discuss data on June 6, 2022 at... Read More

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received acknowledgement of receipt from the U.S. Food and Drug Administration ( FDA ) of the New Drug Application resubmission for Treosulfan ( NDA ) submitted on April 21, 2022, together with a request to submit information in order to complete medac’s NDA resubmission and initiate FDA... Read More

Additional data collection and analysis reconfirms confidence in New Drug Application for Treosulfan NDA resubmission date consistent with previously announced timeline FDA decision still expected within six months of resubmission Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for Treosulfan (... Read More

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference from May 2 to 3, 2022. The conference brings together U.S., Canadian, and international investors interested in the latest developments in the Canadian healthcare sector. Event: Bloom Burton & Co. Healthcare Investor Conference Event Dates: May 2 to 3, 2022 Medexus Presentation: May 2,... Read More

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be participating in the 34 th Annual Roth Conference from March 13 to 15, 2022. Event: 34 th Annual Roth Conference Date: March 13-15, 2022 Location: Dana Point, CA This year’s event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, thematic industry panels, and on-demand... Read More

Medexus has acquired exclusive rights to commercialize Gleolan in the United States, complementing Medexus’s existing rights to Gleolan in Canada Gleolan is an optical imaging agent currently indicated in the United States in patients with glioma as an adjunct for the visualization of malignant tissue or tumor tissue during surgery Gleolan generated $3-4 million U.S. net sales in the fourth calendar quarter of 2021 Medexus... Read More

Medexus will implement a NCIB in respect of its 6% unsecured convertible debentures due 2023 NCIB will commence on February 16, 2022 and is expected to continue for up to 12 months NCIB purchases to deleverage Medexus’s balance sheet and lead to lower overall debt levels and reduced future debt service obligations Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock... Read More

Achieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected in second calendar quarter 2022 with final FDA decision anticipated 2-6 months after resubmission Available liquidity of $10.1 million at end of period Management to host conference call at 8:00 AM Eastern Time on February 10, 2022 TORONTO and CHICAGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc.... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. Medexus’ presentation will be available on-demand to registered attendees via the conference platform... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be participating in two upcoming virtual investor conferences. Sidoti December Micro Cap Virtual Conference Mr. d’Entremont and Mr. Konrad are scheduled to present on Wednesday, December 8, 2021 at 1:00 P.M.... Read More

NDA resubmission expected in second calendar quarter 2022 (previously anticipated timeline) Final FDA decision expected 2 to 6 months after NDA resubmission No additional Phase III study is required Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced that medac clarified with FDA details with regard to the projected NDA resubmission of treosulfan, an... Read More

Achieved $17.9 million revenue driven by continued strength of Rupall ™ Positioned for revenue growth along with expected recovery of IXINITY ® sales Commercially launched Trecondyv ® (treosulfan) in Canada Available liquidity of $9.6 million Management to host conference call at 8:00 AM Eastern Time on November 11th, 2021 Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSX: MDP) (OTCQX: MEDXF) today announced... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021. Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, are scheduled to present as follow: Event: Q4 Investor Summit Date and Time:... Read More

Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed Ian C Wildgoose Brown as the Company’s general counsel and corporate secretary. In this role, Mr. Wildgoose Brown will work with the rest of the Medexus management team to further strengthen and expand the Company’s commercial platform and product portfolio. Mr. Wildgoose Brown is a corporate lawyer... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, November 11, 2021 to discuss the Company’s financial results for the fiscal 2022 second quarter ended September 30, 2021, as well as the Company’s corporate progress and other developments. The Company expects to file its financial statements along... Read More

Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“ medac ”) today announced that the U.S. Food and Drug Administration (“ FDA ”) has granted a Type A meeting to medac for treosulfan, a bifunctional alkylating agent developed for use as part of a conditioning treatment for patients prior to undergoing allogeneic hematopoietic stem cell transplantation. The Type A Meeting... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, are presenting at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021. Management is scheduled to present on Thursday, October 28 th at 3:00 pm Eastern Time / 12:00 pm... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) announced today that it has initiated its first commercial shipment of Trecondyv® (treosulfan) in Canada, following the June 28 th , 2021 Notice of Compliance by Health Canada, which had previously only been distributed under the Health Canada Special Access Program. Trecondyv® is a bifunctional alkylating agent developed for use as part... Read More

Medexus Pharmaceuticals Inc. (the “ Company ”) (TSX: MDP) (OTCQX: MEDXF) today held its annual and special meeting of shareholders virtually. At the meeting, all of the nominees listed in the Company’s management information circular dated August 6, 2021 were elected as directors of the Company until the next annual meeting of shareholders. The detailed voting results for the election of directors are set out below. Name of... Read More

Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Medexus’s presentation will be available on-demand to registered attendees... Read More

Continued strength in unit demand across key product lines Rupall unit demand growth of 44% for the 12 months ending June 30, 2021 Completion of enrollment for IXINITY ® Phase 4 clinical pediatric trials Management to host conference call at 8:00 AM Eastern Time on August 17th, 2021 TORONTO and CHICAGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSX: MDP) (OTCQX: MEDXF)... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “ Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that is has completed enrollment in its Phase 4 Clinical Trial of IXINITY ® , targeting label expansion for pediatric hemophilia B patients. The Trial is investigating IXINITY ® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B, a hereditary bleeding disorder characterized by a... Read More

Medexus Pharmaceuticals Inc. (TSX:MDP) (OTCQX:MEDXF) today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Thursday, August 19 at 11:30 am EST. Ken d'Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, are hosting the presentation and answering questions from investors. To access the live presentation, please use the following information:... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, August 17, 2021 to discuss the Company’s financial results for the fiscal 2022 first quarter ended June 30, 2021, as well as the Company’s corporate progress and other developments. The Company expects to file its financial statements along with its... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) announced today that it will be presenting at the Canaccord Genuity 41 st Annual Growth Conference being held virtually from August 10 th to 12 th , 2021. Canaccord Genuity Growth Conference Presentation Details: Date: Thursday, August 12, 2021 Time: 2:00 P.M. Eastern Time Ken d’Entremont, Chief Executive Officer, and Marcel Konrad, Chief... Read More

Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has scheduled a webinar on Thursday, August 5, 2021 at 10:00 a.m. Eastern Time to discuss the Complete Response Letter (CRL) that the Company’s licensor, medac GmbH, recently received from the Food and Drug Administration (FDA) for treosulfan. As previously disclosed, the New Drug Application (NDA) was submitted in... Read More

Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company ”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced today that medac, Medexus’ licensor for treosulfan, has received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for treosulfan. As previously disclosed, the NDA was submitted for use of treosulfan in combination with fludarabine... Read More

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is stepping down after nearly a decade in the role. Mr. Boivin has agreed to stay on in an advisory capacity in order to help ensure an orderly transition of responsibilities to Mr.... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “ Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship with medac GmbH (“ medac ”) to commercialize treosulfan, a bifunctional alkylating agent, in Canada. Treosulfan will be marketed in Canada under the brand name Trecondyv ® and indicated in combination with fludarabine as part of a conditioning... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “ Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced that it has received a Notice of Compliance (“ NOC ”) from Health Canada to commercialize treosulfan, developed by medac GmbH, in Canada, following the satisfactory review of the submission for the bifunctional alkylating agent. Treosulfan will be marketed in Canada under the brand name Trecondyv ® and indicated in... Read More

Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and available liquidity of $24.8 million at March 31, 2021 Management to host conference call at 8:00 AM Eastern Time on June 17th, 2021 Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial and operating results for the fourth... Read More

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) announced today that it has received final approval for listing of the Company’s common shares (the “Common Shares”) on the Toronto Stock Exchange (the “TSX”). In connection with the graduation of the Common Shares, the Company’s convertible debentures (TSXV:MDP.DB, the “Convertible Debentures”) and certain of the Company’s common share... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Raymond James Human Health Innovation Conference on June 21 st , 2021. Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer, will present a Company overview and provide a business update. The presentation will be webcast live and available... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, June 17, 2021 to discuss the Company’s financial results for the fiscal year-ended March 31, 2021, as well as the Company’s corporate progress and other developments. The Company expects to file its financial statements along... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it has expanded its medical affairs team in preparation for the planned launch of treosulfan, a bifunctional alkylating agent, in the United States. Treosulfan is an innovative, orphan-designated agent developed for use as part of a conditioning treatment for patients undergoing allogeneic... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone Hexacetonide Injectable Suspension, USP (20 mg/ml) (TH) in the United States via the U.S. Food and Drug Administration’s (FDA) CDER Drug Shortage program. More information about the FDA’s Drug Shortage program is available at: FDA Drug... Read More

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) ( TSXV: MDP , OTCQX: MEDXF ), today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021. Ken d’Entremont, Chief Executive Officer of Medexus, and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to host a virtual presentation to investors during the event as follows: 2021 LD... Read More

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has entered into certain amendments (collectively, the “Amendments”) to its existing credit agreements with a syndicate of lenders, agented by MidCap Financial, pursuant to which the Company currently has an outstanding US$10 million secured term loan and a US$20 million secured asset-based revolving... Read More

May 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wednesday and Thursday, May 19 - 20, 2021. The links can also be found at... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Sidoti & Company Virtual Microcap Conference being held on May 19 th - May 20 th , 2021. Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to present on Wednesday, May 19, 2021 at 9:15 AM, Eastern Time. The... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will be participating in the Bloom Burton & Co. Healthcare Investor Conference as well as the Stifel 2021 Canada Cross Sector Insight Conference in the month of April. Bloom Burton & Co. Healthcare Investor Conference Date: Tuesday, April 20, 2021 Time:... Read More

Medexus Pharmaceuticals Inc . (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company’s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted share units (“RSUs”) in lieu of cash director fees for the 2021 calendar year and all non-executive directors have made such election. The RSUs will be issued in accordance with... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1x1 meetings with investors during the 33 rd Annual Roth Conference being held virtually from March 15 th – March 17 th , 2021. This year’s event will consist of 1-on-1 / small group... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced its financial and operating results for the three and nine months ended December 31, 2020. All dollar amounts below are in Canadian dollars unless specified otherwise. Third Quarter Fiscal 2021 Financial Highlights: The Company achieved record revenue of $31.5 million for the three-month period ended... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has initiated the commercial launch of Gleolan® in Canada, which had previously only been distributed under the Health Canada Special Access Program. Gleolan is a 5-aminolevulinic acid hydrochloride (5-ALA) powder for oral solution, and is indicated as an adjunct for the visualization of malignant... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial results for the fiscal 2021 third quarter ended December 31, 2020, as well as the Company’s corporate progress and other developments. The Company expects to file its financial... Read More

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (Frankfurt: P731) announced today that it has closed its previously announced bought deal public offering of 4,581,689 units (the “Units”) at a price of $7.10 per Unit for total gross proceeds of approximately $32,529,992 (the “Offering”), including 597,611 Units sold pursuant to the exercise in full of the over-allotment option granted to the Underwriters... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16 th – February 19 th , 2021. Ken d’Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to present on Wednesday, February 17,... Read More

Orphan Designated Drug with August 2021 PDUFA date Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021 Medexus Pharmaceuticals Inc. (“ Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“ Medexus Pharma... Read More

Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has renewed and expanded its distribution agreement for NYDA ® , a market leading treatment for head lice, through September 26, 2026. The agreement with G. Pohl-Boskamp GmbH & Co KG (" Pohl-Boskamp ") provides the Company with exclusive Canadian distribution rights for NYDA® and includes a... Read More